Literature DB >> 14711519

Expression, purification, crystallization, and NMR studies of the helicase interaction domain of Escherichia coli DnaG primase.

Karin Loscha1, Aaron J Oakley, Bogdan Bancia, Patrick M Schaeffer, Pavel Prosselkov, Gottfried Otting, Matthew C J Wilce, Nicholas E Dixon.   

Abstract

In Escherichia coli, the DnaG primase is the RNA polymerase that synthesizes RNA primers at replication forks. It is composed of three domains, a small N-terminal zinc-binding domain, a larger central domain responsible for RNA synthesis, and a C-terminal domain comprising residues 434-581 [DnaG(434-581)] that interact with the hexameric DnaB helicase. Presumably because of this interaction, it had not been possible previously to express the C-terminal domain in a stably transformed E. coli strain. This problem was overcome by expression of DnaG(434-581) under control of tandem bacteriophage lambda-promoters, and the protein was purified in yields of 4-6 mg/L of culture and studied by NMR. A TOCSY spectrum of a 2mM solution of the protein at pH 7.0, indicated that its structured core comprises residues 444-579. This was consistent with sequence conservation among most-closely related primases. Linewidths in a NOESY spectrum of a 0.5mM sample in 10mM phosphate, pH 6.05, 0.1M NaCl, recorded at 36 degrees C, indicated the protein to be monomeric. Crystals of selenomethionine-substituted DnaG(434-581) obtained by the hanging-drop vapor-diffusion method were body-centered tetragonal, space group I4(1)22, with unit cell parameters a=b=142.2A, c=192.1A, and diffracted beyond 2.7A resolution with synchrotron radiation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14711519     DOI: 10.1016/j.pep.2003.10.001

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  7 in total

1.  Coumarin-based inhibitors of Bacillus anthracis and Staphylococcus aureus replicative DNA helicase: chemical optimization, biological evaluation, and antibacterial activities.

Authors:  Bing Li; Ramdas Pai; Ming Di; Daniel Aiello; Marjorie H Barnes; Michelle M Butler; Tommy F Tashjian; Norton P Peet; Terry L Bowlin; Donald T Moir
Journal:  J Med Chem       Date:  2012-12-11       Impact factor: 7.446

2.  Replication initiation at a distance: determination of the cis- and trans-acting elements of replication origin alpha of plasmid R6K.

Authors:  Mukesh Saxena; Mayuresh Abhyankar; Deepak Bastia
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

3.  A Primase-Induced Conformational Switch Controls the Stability of the Bacterial Replisome.

Authors:  Enrico Monachino; Slobodan Jergic; Jacob S Lewis; Zhi-Qiang Xu; Allen T Y Lo; Valerie L O'Shea; James M Berger; Nicholas E Dixon; Antoine M van Oijen
Journal:  Mol Cell       Date:  2020-05-27       Impact factor: 17.970

4.  Solution structure of the helicase-interaction domain of the primase DnaG: a model for helicase activation.

Authors:  Karl Syson; Jenny Thirlway; Andrea M Hounslow; Panos Soultanas; Jonathan P Waltho
Journal:  Structure       Date:  2005-04       Impact factor: 5.006

5.  The helicase-binding domain of Escherichia coli DnaG primase interacts with the highly conserved C-terminal region of single-stranded DNA-binding protein.

Authors:  Natalie Naue; Monika Beerbaum; Andrea Bogutzki; Peter Schmieder; Ute Curth
Journal:  Nucleic Acids Res       Date:  2013-02-20       Impact factor: 16.971

6.  The unstructured C-terminus of the tau subunit of Escherichia coli DNA polymerase III holoenzyme is the site of interaction with the alpha subunit.

Authors:  Slobodan Jergic; Kiyoshi Ozawa; Neal K Williams; Xun-Cheng Su; Daniel D Scott; Samir M Hamdan; Jeffrey A Crowther; Gottfried Otting; Nicholas E Dixon
Journal:  Nucleic Acids Res       Date:  2007-03-13       Impact factor: 16.971

7.  Fragment-Based Discovery of Inhibitors of the Bacterial DnaG-SSB Interaction.

Authors:  Zorik Chilingaryan; Stephen J Headey; Allen T Y Lo; Zhi-Qiang Xu; Gottfried Otting; Nicholas E Dixon; Martin J Scanlon; Aaron J Oakley
Journal:  Antibiotics (Basel)       Date:  2018-02-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.